Skip to main content
. 2020 Sep 11;12(9):2591. doi: 10.3390/cancers12092591

Figure 2.

Figure 2

Kaplan–Meier curves of overall survival (OS) for patients with metastatic melanoma. (A) OS per treatment year. (B) OS per type of first-line treatment. (C) OS for patients with LDH above or below the upper level of normal (ULN) with or without immune checkpoint-inhibitor (ICI) therapy any time during their treatment course. (D) OS for patients in performance status (PS) 0–1 or 2–3 with or without ICI therapy any time during their treatment course. Ipi/Nivo = Ipilimumab/Nivolumab; IL2/IFN = interleukin-2/interferon-alpha.